HURA NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

TuHURA Biosciences Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 2.17 USD
2.8% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 16.8% above the Trend Line and sits at 50.4% of its 52-week range. The latest completed week returned 2.8%, after a -11.1% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 45/100. Near-term considerations: volume confirmation is below normal; earnings are due in 11d.

Setup score 29 out of 100
Latest Close 2.17 USD 31 Jul 2026
1W Return 2.8% latest completed week
4W Return -11.1% short-term follow-through
12W Return -8.8% quarterly tape
Trend Breadth 25.0% 13 of 52 weeks active
Volume Ratio 0.4x vs 13-week average
What is working
  • The trend backdrop is active with a 13-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
What could go wrong
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
  • Next-week expectancy is negative at 40.83% based on similar historical setup states.
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 2.8% Latest completed week; four-week move -11.1%. Indicator stack 59/8 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 40.83% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 45/100 59 relevant articles in the latest sentiment read. Event risk 11d Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 16.8% above the Trend Line and sits at 50.4% of its 52-week range. The latest completed week returned 2.8%, after a -11.1% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.4x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.4912-week average 0.63

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure9/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership6/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.49Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -11.1% over four weeks, -8.8% over 12 weeks, and -9.6% over one year. The current trend has remained active for 13 consecutive weeks.

Performance by holding period

1W2.8%
4W-11.1%
12W-8.8%
26W305.5%
52W-9.6%
Active trend streak13 weeks
Active weeks in one year13
Trend breadth25.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.50Latest activity-pressure read.
Pressure change-417.3%Four-week change in activity pressure.
Leadership0.29Latest relative-leadership reading.
RS change-94.7%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 67% Model confidence 67%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength32/100Blend of value, momentum, and quality. Underlying universe rank 69; rank 1 is best.
Value42/100Relative valuation strength. Underlying universe rank 59; rank 1 is best.
Quality41/100Profitability and accounting quality. Underlying universe rank 60; rank 1 is best.
Momentum42/100Medium-term price momentum. Underlying universe rank 59; rank 1 is best.
Growth42/100Revenue and earnings growth. Underlying universe rank 59; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-21.1%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-130.9%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
0.0%
Cash dividends relative to market value.
Buyback yield
-19.2%
Net share repurchases relative to market value.
Shareholder yield
-19.2%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.2x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment45/100

Weighted news tone is neutral across 59 relevant articles.

3 positive · 45 neutral · 11 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings11dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-44.4%Distance below the 52-week high.
13-week volatility10.0%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+111.4%Week of 13 Feb.
Worst week-22.1%Week of 3 Apr.
Latest week+2.8%Week of 31 Jul.

Shape of recent returns

Strong gains10
Modest gains3
Flat weeks0
Modest losses3
Sharp losses10
Recent vol10.0%13-week weekly-return volatility.
Base vol23.3%52-week weekly-return volatility.
Up/down split22/30Count of positive and negative weeks in the 52-week window.
Average skew19.3% / -10.7%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape33/100

Trend, activity pressure, participation, and risk combine to a 33/100 tape read.

 Indicator analysis68/100

Latest 12-week confirmation: trend 12/12, activity pressure 9/12, relative leadership 6/12.

Activity pressure 0.49; No reversal markers Next-Week ExpectancyNegative 40.83%

Next-week expectancy is negative with a 40.83% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors38/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 91; Small Cap Core rank 59 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment45/100

Weighted news tone is neutral across 59 relevant articles.

TuHURA Biosciences Inc (HURA) Institutional Confidence Insiders50/100

No recent insider transaction evidence is stored.

 Earnings11d

Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20262.17 USD2.8%1.86 USD14.52 USD-0.500.29976.0KOn
24 Jul 20262.11 USD-6.2%1.81 USD15.42 USD-0.36-2.66846.2KOn
17 Jul 20262.25 USD-5.9%1.77 USD16.39 USD-0.100.932.3MOn
10 Jul 20262.39 USD-2.0%1.72 USD17.37 USD0.071.871.8MOn
3 Jul 20262.44 USD13.0%1.67 USD18.40 USD0.165.342.3MOn
26 Jun 20262.16 USD-16.0%1.66 USD19.51 USD0.19-6.536.9MOn
19 Jun 20262.57 USD10.8%1.65 USD20.40 USD0.285.582.7MOn
12 Jun 20262.32 USD18.1%1.62 USD21.09 USD0.42-2.931.9MOn
5 Jun 20261.97 USD-13.1%1.62 USD21.88 USD0.59-16.592.5MOn
29 May 20262.26 USD-9.6%1.63 USD22.62 USD0.81-9.711.9MOn
22 May 20262.50 USD8.2%1.64 USD23.38 USD0.891.133.3MOn
15 May 20262.31 USD-2.9%1.64 USD24.04 USD0.92-6.512.3MOn
8 May 20262.38 USD2.1%1.64 USD24.68 USD0.99-6.213.7MOn
1 May 20262.33 USD-0.9%1.64 USD25.35 USD1.02-5.603.6MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.